Matthew Mei
机构: Associate Professor, Hematology and Hematopoietic Cell Transplantation
主页: cityofhope.org
每年引用次数
引用次数
引用: 2,955
H-指数: 28
I10-指数 : 64
出版物: 185
Metastatic Genitourinary Malignancies
Przemyslaw Twardowski , Matthew Mei
Landes Bioscience
2
2013
Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Saro H. Armenian , Larry W Kwak , Leslie Popplewell , Robert W. Chen
Blood 130 738 -738
4
2017
Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
Oleg E. Akilov , Michael Maris , Ian W. Flinn , Lubomir Sokol
Blood 136 41 -43
2
2020
Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience
Leslie L. Popplewell , Matthew Mei , Tanya Siddiqi , Jasmine Zain
Blood 136 40 -41
2020
Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma
Ricardo Spielberger , Saro H. Armenian , Larry W Kwak , Auayporn P. Nademanee
Blood 136 19 -20
1
2020
Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
Ibrahim Aldoss , Vinod Pullarkat , Matthew Mei , Anthony Stein
American Journal of Hematology 96 ( 5)
1
2021
Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)
Monzr M. Al Malki , Vinod Pullarkat , Patricia Aoun , Samer K. Khaled
Transplantation and Cellular Therapy 27 ( 3)
2021
Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Larry W. Kwak , Robert Chen , Matthew Mei , Tanya Siddiqi
Transplantation and Cellular Therapy 27 ( 3)
2021
Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. a Pilot Study
Vinod Pullarkat , Ryotaro Nakamura , Amandeep Salhotra , David S. Snyder
2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR 27 ( 3)
2021
Immune thrombocytopenia after immune checkpoint inhibitor therapy.
Vinod Pullarkat , Matthew Mei , Rohan Gupta , Idoroenyi Amanam
British Journal of Haematology 193 ( 3) 677 -681
2021
Therapy-Related ALL Has Distinct Clinical and Pathologic Features Compared to De Novo ALL
Ricardo Spielberger , Ibrahim Aldoss , Monzr M. Al Malki , Vinod Pullarkat
Blood 130 1442 -1442
2017
Trends and Characteristics of Adult Acute Lymphoblastic Leukemia in a Public Safety-Net Hospital
Rohan Gupta , Tamer Othman , An Uche , Idoroenyi Amanam
Blood 132 5160 -5160
2018
Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience
Amandeep Salhotra , Dongyun Yang , Bernard Tegtmeier , Sally Mokhtari
Blood 132 3386 -3386
2018
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
Sonali M. Smith , James Godfrey , Kwang Woo Ahn , Alyssa DiGilio
Cancer 124 ( 12) 2541 -2551
29
2018
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Deepa Jagadeesh , Navneet S Majhail , Yizeng He , Kwang W Ahn
Cancer 126 ( 10) 2279 -2287
2
2020
Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Amrita Y. Krishnan , Matthew Mei , Can-Lan Sun , Sandra H. Thomas
Biology of Blood and Marrow Transplantation 19 ( 2) 260 -265
26
2013
Transplant Outcomes in Patients with AML Carrying IDH 1 and 2 Mutations: Retrospective Study From a Single Center Experience
Amandeep Salhotra , Michelle Afkhami , Dongyun Yang , Sally Mokhtari
Biology of Blood and Marrow Transplantation 24 ( 3)
1
2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Monzr M. Al Malki , Nitya Nathwani , Dongyun Yang , Saro Armenian
Biology of Blood and Marrow Transplantation 24 ( 9) 1828 -1835
7
2018
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis
Amandeep Salhotra , Matthew Mei , Tracey Stiller , Sally Mokhtari
Biology of Blood and Marrow Transplantation 25 ( 2) 287 -292
2
2019
A Retrospective Study of Venetoclax-Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) in High-Risk Acute Myeloid Leukemia (AML) Patients
Karamjeet S. Sandhu , Ibrahim Aldoss , Dongyun Yang , Sally Mokhtari
Biology of Blood and Marrow Transplantation 25 ( 3) S102 -S103
3
2019